C4 Therapeutics, Inc.

Analysis for Ticker: CCCC

C4 Therapeutics is a clinical-stage biotechnology company that uses a proprietary system called TORPEDO to design small molecules that act like biological garbage trucks to destroy proteins that cause diseases like cancer. The scientific narrative sounds like magic, but the financial mathematics are a disaster because the company has accumulated a total deficit of 738,7$ million without ever generating one dollar from selling an actual product. It is like a child trying to run a lemonade stand by buying gold-plated lemons with their parents' credit card while never actually selling a cup of juice. In the year 2025 alone, they incinerated 105,0$ million just to stay in the laboratory, and their only strategy for survival is to print endless pieces of paper called stock at a rate that mathematically crushes the value of every existing shareholder.